menu
    • menu

    Company profile for QurAlis

    NEW Drugs in Dev: 4
    Evonik

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    End-to-end drug development, specializing in high-potency softgels and liquids, providing global partners with a competitive advantage.

    Virtual Booth

    Contact Supplier

    Kewpie is your partner for Sodium Hyaluronate & Hyaluronic Acid// CEP, USDMF, KDMF & JDMF registered.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    QurAlis is developing precision therapeutics for ALS, a terminal disease that causes muscle paralysis through degeneration of the motor system. We are digging deep into the root causes of the multiple sub-forms of this destructive disease and focus our programs on tackling specific disease-causing mechanisms. The QurAlis strategy is to attack ALS one gene at a time by using a transformative system in which cells from ALS pa...
    QurAlis is developing precision therapeutics for ALS, a terminal disease that causes muscle paralysis through degeneration of the motor system. We are digging deep into the root causes of the multiple sub-forms of this destructive disease and focus our programs on tackling specific disease-causing mechanisms. The QurAlis strategy is to attack ALS one gene at a time by using a transformative system in which cells from ALS patients are used to model the disease in the lab to identify new drugs. QurAlis cofounders Kevin Eggan and Clifford Woolf, both Harvard professors, have pioneered this discovery technology for ALS.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    QurAlisUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    700 Main Street, North Cambridge, MA 02139
    Telephone
    Telephone
    (+1) 617.682.6015
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://quralis.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Quralis Confirms QRL-101 Target Engagement in ALS
    Quralis Confirms QRL-101 Target Engagement in ALS

    29 Dec 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251229117640/en/QurAlis-Confirms-Signal-of-Target-Engagement-in-ALS-Patients-in-Phase-1-Clinical-Trial-of-QRL-101-a-Potentially-Best-in-Class-Selective-Kv7.27.3-Ion-Channel-Opener

    BUSINESSWIRE
    29 Dec 2025
    Share Share
    QurAlis To Present At J.P. Morgan Healthcare Conference
    QurAlis To Present At J.P. Morgan Healthcare Conference

    18 Dec 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-12-18/quralis-invited-to-present-at-44th-annual-jp-morgan-healthcare-conference

    PHARMIWEB
    18 Dec 2025
    Share Share
    Quralis To Present QRL-101, Ph 1 Trial Data At AES 2025 Meeting
    Quralis To Present QRL-101, Ph 1 Trial Data At AES 2025 Meeting

    02 Dec 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251202434479/en/QurAlis-to-Present-Data-From-its-Phase-1-Clinical-Trial-of-QRL-101-a-Potential-Best-in-Class-Selective-Kv7.27.3-Ion-Channel-Opener-at-American-Epilepsy-Society-2025-Annual-Meeting

    BUSINESSWIRE
    02 Dec 2025
    Share Share
    Quralis Attends Piper Sandler 37th Annual Healthcare Conference
    Quralis Attends Piper Sandler 37th Annual Healthcare Conference

    20 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251120380958/en/QurAlis-to-Participate-in-Piper-Sandler-37th-Annual-Healthcare-Conference

    BUSINESSWIRE
    20 Nov 2025
    Share Share
    QurAlis Names Manoj Malhotra, M.D., Chief Medical Officer
    QurAlis Names Manoj Malhotra, M.D., Chief Medical Officer

    10 Nov 2025

    // BUSINESS WIRE

    https://www.businesswire.com/news/home/20251110510651/en/QurAlis-Announces-Appointment-of-Manoj-Malhotra-M.D.-as-Chief-Medical-Officer

    BUSINESS WIRE
    10 Nov 2025
    Share Share
    Quralis To Present at November Investor Conferences
    Quralis To Present at November Investor Conferences

    03 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251103871526/en/QurAlis-to-Participate-in-Upcoming-Investor-Conferences-in-November

    BUSINESSWIRE
    03 Nov 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search